生物谷

转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)药物!！辉瑞Vyndaqel/Vyndamax ...

2021年12月21日讯 /生物谷BIOON/ --辉瑞（Pfizer）近日公布了一项事后中期分析报告，数据显示：在治疗5年期间，Vyndaqel（tafamidis ...
生物谷

转甲状腺素蛋白淀粉样变性(ATTR)新药！阿斯利康/Ionis配体偶联反义 ...

eplontersen是一种配体偶联反义(LICA)药物，可减少转甲状腺素蛋白（TTR）的产生。 ATTR淀粉样变性（图片来源：clevelandclinic.org ...
Yahoo Finance

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial ...

CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Business Wire

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment ...

“Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient ...
pharmaphorum

BridgeBio gets EU nod for ATTR cardiomyopathy drug

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...